Nivolumab and pembrolizumab, the anti-PD-1 antibodies, are FDA conditionally approved immune checkpoint inhibitors (ICIs) for HCC as a second line treatment after sorafenib failure [5,6,9]. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.